Anxiety DisordersHealthy VolunteersSet & SettingMedicinal Chemistry & Drug DevelopmentDMT

Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants

In a double‑blind, placebo‑controlled crossover study in 22 healthy adults, continuous DMT infusions showed dose‑proportional pharmacokinetics and rapidly produced dose‑dependent subjective effects that plateaued after 30 minutes with a ceiling for positive effects at 1.8 mg/min, whereas 2.4 mg/min increased anxious ego dissolution and anxiety and produced moderate acute tolerance. A self‑guided titration enabled participants to achieve effects comparable to the 1.8 mg/min dose, supporting dose‑finding and adjustable dosing strategies for future DMT research.

Authors

  • Matthias Liechti
  • Nikhil Varghese
  • Andreas Eckert

Published

Neuropsychopharmacology
individual Study

Abstract

N,N-dimethyltryptamine (DMT) is a serotonergic psychedelic that is known for its short-lasting effects when administered intravenously. Several studies have investigated the administration of intravenous boluses or combinations of a bolus and a subsequent continuous infusion. However, data on dose-dependent acute effects and pharmacokinetics of continuous DMT infusions are lacking. We used a double-blind, randomized, placebo-controlled, crossover design in 22 healthy participants (11 women, 11 men) who received placebo and DMT (0.6, 1.2, 1.8, and 2.4 mg/min) over an infusion duration of 120 min. We also tested a self-guided titration scheme that allowed participants to adjust the DMT dose rate at prespecified time points to achieve their desired level of subjective effects. Outcome measures included subjective effects, autonomic effects, adverse effects, plasma hormone concentrations, and pharmacokinetics up to 3 h after starting the infusion. DMT infusions exhibited dose-proportional pharmacokinetics and rapidly induced dose-dependent subjective effects that reached a plateau after 30 min. A ceiling effect was observed for “good drug effect” at 1.8 mg/min. The 2.4 mg/min dose of DMT induced greater anxious ego dissolution than the 1.8 mg/min dose and induced significant anxiety compared with placebo. We observed moderate acute tolerance to acute effects of DMT. In the self-guided titration session, the participants opted for moderate to strong psychedelic effects, comparable in intensity to the 1.8 mg/min DMT dose rate in the randomized dosing sessions. These results may assist with dose finding for future DMT research and demonstrate that acute subjective effects of DMT can be rapidly adjusted through dose titration.

Available with Blossom Pro

Research Summary of 'Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants'

Introduction

N,N-dimethyltryptamine (DMT) is a short-acting serotonergic psychedelic whose acute psychoactive effects are primarily mediated at 5-HT2A receptors. Prior clinical work has most commonly delivered DMT by intravenous bolus or by combining a bolus with a continuous infusion; boluses tend to produce very rapid, intense and sometimes poorly tolerated effects, whereas some continuous infusions without a bolus have produced milder, gradually stabilising effects. However, dose-dependent acute effects and detailed pharmacokinetics of longer continuous DMT infusions across a range of infusion rates remain poorly characterised, and formal testing of within-session self-titration has not been reported in a controlled setting. Erne and colleagues therefore designed a double-blind, placebo-controlled, within-subject crossover study to map acute subjective, autonomic, endocrine and pharmacokinetic responses to four continuous intravenous DMT infusion rates (0.6, 1.2, 1.8 and 2.4 mg/min) administered over 120 min, and to evaluate a subsequent open-label, self-guided titration session in which participants could adjust dose rate at prespecified times to reach a desired level of subjective effect. The study aimed to inform dose selection for future research and to test whether acute subjective states can be rapidly and safely modulated by within-session dose adjustment.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (22)

Papers cited by this study that are also in Blossom

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)

Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans

Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)

145 cited
Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics

Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)

Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects

Aicher, H. D., Mueller, M. J., Dornbierer, D. A. et al. · Frontiers in Psychiatry (2024)

24 cited
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants

Vogt, S. B., Ley, L., Erne, L. et al. · Translational Psychiatry (2023)

64 cited
Psychological and physiological effects of extended DMT

Luan, L. X., Eckernäs, E., Ashton, M. et al. · Journal of Psychopharmacology (2023)

Pharmacokinetics of N,N-dimethyltryptamine in Humans

Good, M., Joel, Z., Benway, T. et al. · European Journal of Pharmacology (2022)

Effects of DMT on mental health outcomes in healthy volunteers

Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)

29 cited
Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial

Falchi, M., Wießner, I., Silva, S. R. B. et al. · European Neuropsychopharmacology (2024)

18 cited
Show all 22 references
Psychometric evaluation of the altered states of consciousness rating scale (OAV)

Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)

Acute effects of lysergic acid diethylamide in healthy subjects

Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)

Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects

Holze, F., Duthaler, U., Vizeli, P. et al. · British Journal of Clinical Pharmacology (2019)

118 cited
Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects

Strajhar, P., Schmid, Y., Liakoni, E. et al. · Journal of Neuroendocrinology (2016)

Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants

Vizeli, P., Studerus, E., Holze, F. et al. · Translational Psychiatry (2024)

Prediction of psilocybin response in healthy volunteers

Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)

Cited By (4)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Acute dose-dependent effects and self-guided... — Research Summary & Context | Blossom